EAST RUTHERFORD, N.J.
, Dec. 16, 2013 /PRNewswire/
-- Cambrex Corporation
(NYSE: CBM, "Cambrex") announced that the US Food and Drug Administration (FDA) completed an inspection of Cambrex's active pharmaceutical ingredient (API) manufacturing facility in Charles City, Iowa. The inspection found the site to be compliant with the principles and guidelines of Good Manufacturing Practice (GMP) and no Form 483 observations were issued. The US FDA authorities inspected the facility from
July 31 to August 2, 2013
, Vice President Operations and Charles City Site Director commented, "We are very pleased with the results of this latest FDA inspection, which further strengthens our track record of outstanding regulatory compliance. We commit significant resources and work diligently to maintain high quality standards and continuously improve quality platforms within Cambrex."
The entire facility and the quality systems used for the manufacture and release of APIs and food grade products were subject to a detailed compliance inspection. This follows successful inspections at Charles City made previously by the US FDA in
, neither of which resulted in any issued 483 observations, the Korean FDA in
and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK
, after which a GMP certificate for a drug product intermediate was issued.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit
SOURCE Cambrex Corporation